Janux Therapeutics shares
more than doubled in value before the bell on Tuesday after the
drug developer reported encouraging interim early-stage data
for its experimental therapy to treat an.
Janux Therapeutics (NASDAQ:JANX – Get Free Report)‘s stock had its “outperform” rating reissued by equities researchers at William Blair in a report issued on Tuesday, RTT News reports. JANX has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Janux Therapeutics […]
Janux Therapeutics (NASDAQ:JANX – Get Free Report) had its target price hoisted by Wedbush from $24.00 to $53.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price objective would indicate a potential upside of 250.99% from the company’s current […]
JANX Therapeutics' updates in cancer treatment: JANX007 shows promising PSA declines in prostate cancer trials, while JANX008 exhibits encouraging clinical activity in solid tumors.
Janux Therapeutics (NASDAQ:JANX – Get Free Report) had its price target hoisted by Wedbush from $24.00 to $53.00 in a report released on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s target price would suggest a potential upside of 250.99% from the company’s previous close. Separately, HC Wainwright reiterated […]